Lifecare ASA is a Norway-based company that develops miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers. Lifecare's activities are concentrated on the development of sensor for use as a medical product, initially the sensor Sencell for continuous monitoring of glucose (blood sugar) for people with diabetes. The technology is suitable for detecting and measuring a wide range of molecules that can occur in the human body, based on variations in osmotic pressure.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
20/07/26	NOK 0.3000	+5.26%	1,094,805
17/07/26	NOK 0.2850	-3.55%	793,744
16/07/26	NOK 0.2955	-0.17%	525,265
15/07/26	NOK 0.2960	+5.71%	1,402,079
14/07/26	NOK 0.2800	+1.45%	750,314

Real-time Oslo Bors

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Oslo Bors Other stock markets 12:45:00 21/07/26 am AEST			5-day change	1st Jan Change
0.3000 ^NOK	+5.26%		+8.70%	-90.80%

02/07	Lifecare Completes Production Transfer and Provides Update on Longevity Programme	CI
29/06	Lifecare Transfers Operations from Germany to Norway, UK	MT

Market Cap	89.44M 9.25M 8.1M 7.48M 6.89M 12.91M 893M 13.2M 89.36M 35.05M 436M 34.75M 33.99M 1.5B	P/E 2026 *	-0.79x	P/E 2027 *	-1.07x
Enterprise Value	125M 12.97M 11.36M 10.49M 9.66M 18.11M 1.25B 18.51M 125M 49.16M 612M 48.74M 47.68M 2.1B	EV / Sales 2026 *	-	EV / Sales 2027 *	25.5x
Free-Float	89.66%	Yield 2026 *	-	Yield 2027 *	-

02/07	Lifecare Completes Production Transfer and Provides Update on Longevity Programme	CI
29/06	Lifecare Transfers Operations from Germany to Norway, UK	MT
27/06	Lifecare ASA Discontinues Operations of Lifecare Germany GmbH	CI
10/06	Lifecare Completes First Six-Month Implant Evaluation With Continued Functionality and No Adverse Biological Response	CI
15/05	Lifecare ASA, Q1 2026 Earnings Call, May 15, 2026
15/05	Lifecare ASA Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
15/05	Lifecare Q1 operating loss NOK 31.5 mln	RE
24/04	Lifecare ASA Approves Board Appointments	CI
27/03	Lifecare ASA Announces Operational Restructuring And Centralization Of Operations	CI
27/03	Lifecare ASA Announces Discontinuation of the Business Operations of Lifecare Germany GmbH	CI
27/03	Lifecare ASA to Close German Operations, Consolidate Activities Under Planned Centralization	MT
16/03	Lifecare Chief Scientific Officer to Step Down	MT
14/03	Andreas Pfützner to Step Down as Chief Scientific Officer of Lifecare ASA	CI

02/07	LIFE: Update on production transfer and longevity programme	AQ
27/06	LIFE: Operational update regarding Lifecare Germany GmbH (i.L)	PU
22/06	LIFE: Independent tissue analysis confirms no adverse tissue response after six months of implantation	AQ
13/06	Lifecare ASA: Final results following expiry of exercise period for Warrants Series 2 issued in connection with Rights Issue	PU
11/06	Lifecare ASA: Mandatory notification of trade	PU

Lifecare ASA Stock

Stocks

LIFE

NO0013355859

Biotechnology & Medical Research

Valuation: Lifecare ASA

Chart: Lifecare ASA

Latest news : Lifecare ASA

Last Transcript: Lifecare ASA

Analysts' recommendations: Lifecare ASA

Press Releases: Lifecare ASA

News in other languages: Lifecare ASA

Quotes and Performance

Course Extremes

Managers and Directors: Lifecare ASA

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	+5.26%
1 week	+8.70%
Current month	+3.81%
1 month	-5.36%
3 months	-28.57%
6 months	-58.79%
Current year	-90.80%

1 week	0.27	0.3
1 month	0.27	0.38
Current year	0.27	2
1 year	0.27	23.5
3 years	0.27	82.16
5 years	0.27	82.16
10 years	0.27	117

Manager	Title	Age	Since
Joacim Holter CEO	Chief Executive Officer	50	07/09/2020
Petter Nielsen DFI	Director of Finance/CFO	-	01/04/2026
Torsten Ernst PRN	Corporate Officer/Principal	-	01/03/2024

Director	Title	Age	Since
Trine Teigland BRD	Director/Board Member	-	26/06/2020
Morten Foros Krohnstad CHM	Chairman	-	08/05/2021
Lutz Heinemann BRD	Director/Board Member	-	20/11/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LIFECARE ASA	+5.26%	+8.70%	-93.95%	-98.83%	8.82M
LONZA GROUP AG	-0.49%	-3.58%	-0.84%	+2.13%	49.18B
REVOLUTION MEDICINES, INC.	-3.10%	-3.47%	+370.99%	+567.62%	39.58B
BEONE MEDICINES AG	-0.46%	+3.98%	+5.44%	+60.79%	34.69B
IQVIA HOLDINGS INC.	-1.14%	-1.90%	+26.94%	-9.56%	34.42B
CELLTRION, INC.	-1.82%	-1.48%	+0.52%	+32.02%	27.11B
ASCENDIS PHARMA A/S	-3.54%	-6.91%	-	-	16.21B
MEDPACE HOLDINGS, INC.	-1.82%	-1.91%	+69.28%	+112.51%	15.36B
EUROFINS SCIENTIFIC SE	+1.17%	+3.10%	+15.87%	+16.79%	14.05B
ICON PUBLIC LIMITED COMPANY	-2.25%	-0.92%	+15.77%	-32.78%	13.02B
Average	-0.82%	+0.17%	+45.56%	+72.30%	24.36B
Weighted average by Cap.	-1.43%	-0.38%	+75.91%	+117.64%

	2026 *	2027 *
Net sales	-	5M 517K 453K 418K 385K 722K 49.9M 738K 5M 1.96M 24.38M 1.94M 1.9M 83.86M
Net income	-86M -8.89M -7.79M -7.19M -6.62M -12.42M -858M -12.69M -85.92M -33.7M -419M -33.42M -32.69M -1.44B	-82M -8.48M -7.43M -6.86M -6.31M -11.84M -818M -12.1M -81.93M -32.14M -400M -31.86M -31.17M -1.38B
Net Debt	36M 3.72M 3.26M 3.01M 2.77M 5.2M 359M 5.31M 35.97M 14.11M 176M 13.99M 13.68M 604M	38M 3.93M 3.44M 3.18M 2.93M 5.49M 379M 5.61M 37.97M 14.89M 185M 14.77M 14.44M 637M